摘要:
An iron-chromium-aluminum alloy with improved heat resistance, low chromium vaporization rate and good processability, comprising (in % by mass), 2.0 to 4.5% Al, 12 to 25% Cr, 1.0 to 4% W, 0.25 to 2.0% Nb, 0.05 to 1.2% Si, 0.001 to 0.70% Mn, 0.001 to 0.030% C, 0.0001 to 0.05% Mg, 0.0001 to 0.03% Ca, 0.001 to 0.030% P, max. 0.03% N, max. 0.01% S, remainder iron and the usual melting-related impurities.
摘要:
An iron-chromium-aluminum alloy with improved heat resistance, low chromium vaporization rate and good processability, comprising (in % by mass), 2.0 to 4.5% Al, 12 to 25% Cr, 1.0 to 4% W, 0.25 to 2.0% Nb, 0.05 to 1.2% Si, 0.001 to 0.70% Mn, 0.001 to 0.030% C, 0.0001 to 0.05% Mg, 0.0001 to 0.03% Ca, 0.001 to 0.030% P, max. 0.03% N, max. 0.01% S, remainder iron and the usual melting-related impurities.
摘要:
A cannula assembly (10) comprising a hub (76) and a cannula (12) mounted in the hub (76). The cannula defines an inner space (36). The cannula comprises a distal end (16) and a proximal end (18). A first medicament (40) is provided in the inner space of the cannula. In one arrangement, the hub of the cannula assembly is configured to be coupled to an injection device (26). The cannula assembly may be removably or permanently coupled to the injection device containing a second medicament (17).
摘要:
Provided herein are compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof, which are useful as pharmaceutical compositions for the treatment of metabolic diseases and disorders.
摘要:
The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R1, R2, R3, R4, R5, A1, A2, and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.
摘要:
The invention is concerned with novel imidazopyrimidine derivatives of formula (I) wherein R1, R2 and R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.
摘要:
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.
摘要:
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 and n are as described herein, compositions including the compounds and methods of using the compounds.
摘要:
This invention relates to novel indazole derivatives of formula I: wherein R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments.
摘要:
Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.